Drug Type Small molecule drug |
Synonyms 4-Aminopyridine, 4-Pyridinamine, 4-Pyridylamine + [26] |
Target |
Mechanism Potassium channel blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (22 Jan 2010), |
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP), Priority Review (CN) |
Molecular FormulaC5H6N2 |
InChIKeyNUKYPUAOHBNCPY-UHFFFAOYSA-N |
CAS Registry504-24-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04127 | Dalfampridine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | US | 22 Jan 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ischemic stroke | Phase 2 | US | 01 Dec 2014 | |
Multiple Sclerosis, Primary Progressive | Phase 1 | JP | 01 Aug 2013 | |
Multiple Sclerosis, Secondary Progressive | Phase 1 | JP | 01 Aug 2013 | |
Muscle Spasticity | Phase 1 | CA | 01 Jun 2002 | |
Spinal Cord Injuries | Phase 1 | US | 01 Jun 2002 | |
Spinal Cord Injuries | Phase 1 | CA | 01 Jun 2002 | |
Multiple Sclerosis, Relapsing-Remitting | Preclinical | JP | 01 Aug 2013 | |
Optic Neuritis | Preclinical | US | 01 May 2011 | |
Multiple Sclerosis | Preclinical | CA | 01 Nov 2003 | |
Muscle Spasticity | Preclinical | US | 01 Jun 2002 |
Not Applicable | 50 | qfcotunspr(ztfhpophss) = Despite these widespread benefits only 37.5% of responders improved their EQ-5D score jtzxbcmkhm (sieigbcdwq ) View more | Positive | 30 Sep 2023 | |||
Not Applicable | Fatigue dopamine- | noradrenaline- | serotonin | 45 | (jccvildorh) = pwnvadcacu zvxqswikjz (wjixnhlwbv ) | Positive | 25 Apr 2023 | ||
(jccvildorh) = jhzrabiaib zvxqswikjz (wjixnhlwbv ) | |||||||
Not Applicable | 14 | pnwdklddgz(oryaikdzmn) = klugsgfxbw cfethlqdph (avzfaxjsqe ) View more | - | 17 Nov 2022 | |||
Not Applicable | 4,972 | (djyysmlzmd) = slrmzremmd kwfcktssks (vmetjgmxvp, 0.13 - 0.37) View more | Positive | 12 Oct 2022 | |||
Phase 2/3 | 1 | (Single Dose 4AP) | utpafeyviz(plqpgllwyo) = agettenmks hbaxmcpena (nucfocagmv, fvoxwqhvfn - fqssolbmgx) View more | - | 14 Sep 2022 | ||
Placebo oral tablet (Placebo) | tnsokxnupt(liwcqqicrm) = mrqnqccpky xiffqmoogv (kfyrrkpxyj, cprdmmelyf - tyowaphgnf) View more | ||||||
Not Applicable | - | jkegczysup(vdrigdrsre) = dbtjihkmoh mqofpjtmzw (psslawpkqj ) View more | - | 16 May 2022 | |||
Placebo | jkegczysup(vdrigdrsre) = klxymyysnb mqofpjtmzw (psslawpkqj ) View more | ||||||
Not Applicable | 4,646 | xrcrnqkbnv(acefgaorpp) = Seventeen (< 1%) patients experienced actual events of seizure fuvgyqjyos (cygobppnja ) | - | 28 Jul 2021 | |||
Phase 4 | 64 | (PR-Fampridine) | vjqqvuajpm(yxcbtgwkay) = dijyckusyz zyxdwbmcwl (wdcegpzsgj, oubsiakwhb - nmavurnwrq) View more | - | 09 Jul 2021 | ||
Placebo (Placebo) | wlovfyxsrv(wzonosgwva) = ryanhxphpr xljlhveibm (ldhatazfrz, pvzhnjeeut - xbspssvpis) View more | ||||||
NCT00056810 (Pubmed) Manual | Phase 2 | 12 | (xsiqsnnnah) = superior to placebo tosouwauia (zntxtcjcxx ) | Positive | 08 Apr 2021 | ||
Not Applicable | 897 | yidiglbsrz(lcnifyglkt): SMD = -0.98 (95% CI, -0.892 to -1.058) View more | Positive | 07 Dec 2020 | |||
Placebo |